NASDAQ:MCRB

Seres Therapeutics News Headlines

$7.12
-0.56 (-7.29 %)
(As of 07/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.02
$7.62
50-Day Range
$7.12
$24.36
52-Week Range
$3.67
$38.50
Volume2.15 million shs
Average Volume1.11 million shs
Market Capitalization$652.74 million
P/E RatioN/A
Dividend YieldN/A
Beta3.93

Seres Therapeutics (NASDAQ MCRB) News Headlines Today

SourceHeadline
Seres Therapeutics (NASDAQ:MCRB) PT Lowered to $29.00Seres Therapeutics (NASDAQ:MCRB) PT Lowered to $29.00
marketbeat.com - July 23 at 8:19 AM
Zacks Investment Research Upgrades Seres Therapeutics (NASDAQ:MCRB) to HoldZacks Investment Research Upgrades Seres Therapeutics (NASDAQ:MCRB) to Hold
marketbeat.com - July 8 at 6:31 AM
Zacks: Brokerages Anticipate Seres Therapeutics, Inc. (NASDAQ:MCRB) Will Post Earnings of -$0.41 Per ShareZacks: Brokerages Anticipate Seres Therapeutics, Inc. (NASDAQ:MCRB) Will Post Earnings of -$0.41 Per Share
americanbankingnews.com - July 27 at 3:10 PM
Seres Therapeutics (NASDAQ:MCRB) Shares Up 6.5%Seres Therapeutics (NASDAQ:MCRB) Shares Up 6.5%
americanbankingnews.com - July 26 at 12:01 PM
Analyst Ratings For Seres TherapeuticsAnalyst Ratings For Seres Therapeutics
markets.businessinsider.com - July 23 at 5:54 PM
Seres Therapeutics (NASDAQ:MCRB) Sees Unusually-High Trading Volume on Analyst UpgradeSeres Therapeutics (NASDAQ:MCRB) Sees Unusually-High Trading Volume on Analyst Upgrade
americanbankingnews.com - July 23 at 11:45 AM
Seres Therapeutics (NASDAQ:MCRB) Price Target Cut to $29.00 by Analysts at Canaccord GenuitySeres Therapeutics (NASDAQ:MCRB) Price Target Cut to $29.00 by Analysts at Canaccord Genuity
americanbankingnews.com - July 23 at 11:06 AM
Chardan Capital Increases Seres Therapeutics (NASDAQ:MCRB) Price Target to $30.00Chardan Capital Increases Seres Therapeutics (NASDAQ:MCRB) Price Target to $30.00
americanbankingnews.com - July 23 at 11:06 AM
Seres Therapeutics (NASDAQ:MCRB) PT Lowered to $25.00Seres Therapeutics (NASDAQ:MCRB) PT Lowered to $25.00
americanbankingnews.com - July 23 at 11:06 AM
Seres Therapeutics (NASDAQ:MCRB) Downgraded by The Goldman Sachs GroupSeres Therapeutics (NASDAQ:MCRB) Downgraded by The Goldman Sachs Group
americanbankingnews.com - July 23 at 10:16 AM
Is Seres Therapeutics Still A Buy After Disappointing SER-287 Topline Results?Is Seres Therapeutics Still A Buy After Disappointing SER-287 Topline Results?
finance.yahoo.com - July 23 at 7:53 AM
Seres Therapeutics (NASDAQ:MCRB) Price Target Lowered to $18.00 at OppenheimerSeres Therapeutics (NASDAQ:MCRB) Price Target Lowered to $18.00 at Oppenheimer
americanbankingnews.com - July 22 at 8:48 PM
Piper Sandler Trims Seres Therapeutics (NASDAQ:MCRB) Target Price to $32.00Piper Sandler Trims Seres Therapeutics (NASDAQ:MCRB) Target Price to $32.00
americanbankingnews.com - July 22 at 5:04 PM
Seres Stock Tanks After Failed Ulcerative Colitis Drug TestSeres Stock Tanks After Failed Ulcerative Colitis Drug Test
msn.com - July 22 at 3:02 PM
Cambridge microbiome startups shares sliced in half after key trial failureCambridge microbiome startup's shares sliced in half after key trial failure
bizjournals.com - July 22 at 3:02 PM
Seres Therapeutics (NASDAQ:MCRB) Shares Gap Down to $20.83Seres Therapeutics (NASDAQ:MCRB) Shares Gap Down to $20.83
americanbankingnews.com - July 22 at 11:00 AM
BRIEF-Seres Announces Topline Results For SER-287 Phase 2B Study In Mild-To-Moderate Ulcerative ColitisBRIEF-Seres Announces Topline Results For SER-287 Phase 2B Study In Mild-To-Moderate Ulcerative Colitis
msn.com - July 22 at 8:33 AM
Seres Therapeutics : Phase 2b Study On Ulcerative Colitis Fails To Meet Main Goal; Stock PlungesSeres Therapeutics : Phase 2b Study On Ulcerative Colitis Fails To Meet Main Goal; Stock Plunges
markets.businessinsider.com - July 22 at 8:33 AM
Seres Therapeutics Announces Topline Results for SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative ColitisSeres Therapeutics Announces Topline Results for SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative Colitis
finance.yahoo.com - July 22 at 8:33 AM
Seres Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2b Study of SER-287 to Treat Mild-to-Moderate Ulcerative ColitisSeres Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2b Study of SER-287 to Treat Mild-to-Moderate Ulcerative Colitis
finance.yahoo.com - July 22 at 8:33 AM
Seres shares fall 55% after the company says its colitis drug failed in mid-stage clinical trialSeres shares fall 55% after the company says its colitis drug failed in mid-stage clinical trial
finance.yahoo.com - July 22 at 8:33 AM
Hedge Funds Have Never Been This Bullish On Seres Therapeutics Inc (MCRB)Hedge Funds Have Never Been This Bullish On Seres Therapeutics Inc (MCRB)
finance.yahoo.com - July 21 at 2:14 PM
Noteworthy Tuesday Option Activity: MCRB, PENN, CVNANoteworthy Tuesday Option Activity: MCRB, PENN, CVNA
nasdaq.com - July 20 at 6:47 PM
Analysts Estimate Seres Therapeutics (MCRB) to Report a Decline in Earnings: What to Look Out forAnalysts Estimate Seres Therapeutics (MCRB) to Report a Decline in Earnings: What to Look Out for
finance.yahoo.com - July 20 at 6:47 PM
Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives Consensus Rating of "Buy" from AnalystsSeres Therapeutics, Inc. (NASDAQ:MCRB) Receives Consensus Rating of "Buy" from Analysts
americanbankingnews.com - July 18 at 1:46 PM
Seres Therapeutics (NASDAQ:MCRB) Trading 3.1% Higher Seres Therapeutics (NASDAQ:MCRB) Trading 3.1% Higher
americanbankingnews.com - July 16 at 12:22 PM
Seres Therapeutics (NASDAQ:MCRB) Receives New Coverage from Analysts at Chardan CapitalSeres Therapeutics (NASDAQ:MCRB) Receives New Coverage from Analysts at Chardan Capital
americanbankingnews.com - July 10 at 1:24 PM
Seres Therapeutics (NASDAQ:MCRB) Trading Down 1.8%Seres Therapeutics (NASDAQ:MCRB) Trading Down 1.8%
americanbankingnews.com - July 9 at 11:37 AM
Seres Therapeutics (MCRB) Buy Rating Reiterated at Chardan CapitalSeres Therapeutics' (MCRB) Buy Rating Reiterated at Chardan Capital
americanbankingnews.com - July 7 at 6:32 AM
Seres Therapeutics (NASDAQ:MCRB) Shares Gap Up to $21.17Seres Therapeutics (NASDAQ:MCRB) Shares Gap Up to $21.17
americanbankingnews.com - July 6 at 11:00 AM
Nestlé Bets $525M On Seres Therapeutics Microbiome Drug For Infectious DiseasesNestlé Bets $525M On Seres Therapeutics Microbiome Drug For Infectious Diseases
finance.yahoo.com - July 1 at 2:10 PM
BRIEF-Seres, Nestlé Health Science Announce SER-109 Co-Commercialization License AgreementBRIEF-Seres, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement
msn.com - July 1 at 9:10 AM
Seres Therapeutics in Commercialization Pact With Nestle Health ScienceSeres Therapeutics in Commercialization Pact With Nestle Health Science
marketwatch.com - July 1 at 9:10 AM
MCRB Crosses Above Key Moving Average LevelMCRB Crosses Above Key Moving Average Level
nasdaq.com - June 28 at 3:44 PM
Seres Therapeutics to Host Virtual Investor Event on June 21, 2021Seres Therapeutics to Host Virtual Investor Event on June 21, 2021
finance.yahoo.com - June 10 at 8:56 AM
Seres Therapeutics to Present at JMP Securities Life Sciences ConferenceSeres Therapeutics to Present at JMP Securities Life Sciences Conference
finance.yahoo.com - June 10 at 8:56 AM
Seres Therapeutics Presents Research from its Early-Stage Microbiome Therapeutic Oncology Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingSeres Therapeutics Presents Research from its Early-Stage Microbiome Therapeutic Oncology Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - June 4 at 3:08 PM
First Week of MCRB October 15th Options TradingFirst Week of MCRB October 15th Options Trading
nasdaq.com - June 2 at 7:42 PM
Seres Announces FDA Clearance Of IND For SER-155Seres Announces FDA Clearance Of IND For SER-155
nasdaq.com - June 1 at 12:55 PM
Seres Therapeutics Announces FDA Clearance Of IND For SER-155Seres Therapeutics Announces FDA Clearance Of IND For SER-155
nasdaq.com - June 1 at 12:55 PM
Seres Therapeutics Announces FDA Clearance of IND for SER-155, an Investigational Microbiome Therapeutic for the Prevention of Antibiotic-Resistant Bacterial Infections and Graft-versus-Host Disease (GvHD)Seres Therapeutics Announces FDA Clearance of IND for SER-155, an Investigational Microbiome Therapeutic for the Prevention of Antibiotic-Resistant Bacterial Infections and Graft-versus-Host Disease (GvHD)
finance.yahoo.com - June 1 at 12:55 PM
Seres Therapeutics to Present at Upcoming Virtual Investor ConferencesSeres Therapeutics to Present at Upcoming Virtual Investor Conferences
finance.yahoo.com - May 25 at 9:40 AM
Seres Therapeutics Presents Data Across its Broad Microbiome Pipeline Including New 24-Week Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at ...Seres Therapeutics Presents Data Across its Broad Microbiome Pipeline Including New 24-Week Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at ...
businesswire.com - May 22 at 12:26 AM
Seres Therapeutics Presents Data Across its Broad Microbiome Pipeline Including New 24-Week Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at Digestive Disease Week 2021Seres Therapeutics Presents Data Across its Broad Microbiome Pipeline Including New 24-Week Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at Digestive Disease Week 2021
finance.yahoo.com - May 21 at 2:39 PM
Seres Therapeutics Announces David Arkowitz to Join as Executive Vice President, Chief Financial Officer and Head of Business DevelopmentSeres Therapeutics Announces David Arkowitz to Join as Executive Vice President, Chief Financial Officer and Head of Business Development
finance.yahoo.com - May 20 at 12:25 PM
Seres Therapeutics to Present Clinical Research on the Microbiome’s Impact on Allogeneic Hematopoietic Stem Cell Transplantation and Cancer Immunotherapy at the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingSeres Therapeutics to Present Clinical Research on the Microbiome’s Impact on Allogeneic Hematopoietic Stem Cell Transplantation and Cancer Immunotherapy at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - May 19 at 7:58 PM
Seres Therapeutics to Present at RBC Capital Markets 2021 Global Healthcare ConferenceSeres Therapeutics to Present at RBC Capital Markets 2021 Global Healthcare Conference
finance.yahoo.com - May 12 at 7:59 AM
Seres Therapeutics to Present Key Data on Investigational Microbiome Therapeutics for Recurrent C. difficile Infection and Ulcerative Colitis at the Digestive Disease Week (DDW) Annual MeetingSeres Therapeutics to Present Key Data on Investigational Microbiome Therapeutics for Recurrent C. difficile Infection and Ulcerative Colitis at the Digestive Disease Week (DDW) Annual Meeting
finance.yahoo.com - May 11 at 10:40 AM
Seres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Slashed This Years EstimatesSeres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Slashed This Year's Estimates
nasdaq.com - May 9 at 5:27 PM
Bearish: Analysts Just Cut Their Seres Therapeutics, Inc. (NASDAQ:MCRB) Revenue and EPS estimatesBearish: Analysts Just Cut Their Seres Therapeutics, Inc. (NASDAQ:MCRB) Revenue and EPS estimates
finance.yahoo.com - May 9 at 12:26 PM
Seres Therapeutics Reports First Quarter 2021 Financial Results and Provides Business UpdatesSeres Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates
finance.yahoo.com - May 4 at 8:18 AM
What Wall Street expects from Seres Therapeuticss earningsWhat Wall Street expects from Seres Therapeutics's earnings
markets.businessinsider.com - May 2 at 11:27 PM
This page was last updated on 7/27/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.